376 related articles for article (PubMed ID: 21649691)
21. Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets.
Asplund Persson A; Zalavary S; Lindström E; Whiss PA; Bengtsson T; Grenegård M
Eur J Pharmacol; 2005 Jul; 517(3):149-57. PubMed ID: 15963495
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
Minami N; Suzuki Y; Yamamoto M; Kihira H; Imai E; Wada H; Kimura Y; Ikeda Y; Shiku H; Nishikawa M
Life Sci; 1997; 61(25):PL 383-9. PubMed ID: 9416770
[TBL] [Abstract][Full Text] [Related]
23. Interplay between milrinone and adenosine in the inhibition of human platelet response.
Anfossi G; Massucco P; Piretto V; Mularoni E; Cavalot F; Mattiello L; Trovati M
Gen Pharmacol; 1996 Oct; 27(7):1149-54. PubMed ID: 8981060
[TBL] [Abstract][Full Text] [Related]
24. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
25. Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
Li H; Cone J; Fong M; Kambayashi J; Yoshitake M; Liu Y
Cardiovasc Drugs Ther; 2005 Jan; 19(1):41-8. PubMed ID: 15883755
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Ikeda Y
Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
[No Abstract] [Full Text] [Related]
27. Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity.
Yagi H; Yamaguchi N; Shida Y; Hayakawa M; Matsumoto M; Sugimoto M; Wada H; Tsubaki K; Fujimura Y
Eur J Pharmacol; 2012 Sep; 691(1-3):151-5. PubMed ID: 22796451
[TBL] [Abstract][Full Text] [Related]
28. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
[TBL] [Abstract][Full Text] [Related]
29. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets.
Hayashi H; Sudo T
Thromb Haemost; 2009 Aug; 102(2):327-35. PubMed ID: 19652884
[TBL] [Abstract][Full Text] [Related]
30. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood.
Kariyazono H; Nakamura K; Arima J; Ayukawa O; Onimaru S; Masuda H; Iguro Y; Majima HJ; Sakata R; Yamada K
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):157-67. PubMed ID: 15091003
[TBL] [Abstract][Full Text] [Related]
32. [Selective type III phosphodiesterase inhibitor as an antithrombotic agent].
Kimura Y
Nihon Yakurigaku Zasshi; 1995 Sep; 106(3):205-16. PubMed ID: 8529965
[TBL] [Abstract][Full Text] [Related]
33. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M
J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
[TBL] [Abstract][Full Text] [Related]
34. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Sudo T; Ito H; Ozeki Y; Kimura Y
Br J Pharmacol; 2001 Aug; 133(8):1396-404. PubMed ID: 11498527
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole.
Liu Y; Oh SJ; Chang KH; Kim YG; Lee MY
Biochem Pharmacol; 2013 Oct; 86(7):914-25. PubMed ID: 23876340
[TBL] [Abstract][Full Text] [Related]
36. Construction and study of blood purification membrane modified with PDE inhibitor: Investigation of antiplatelet activity and hemocompatibility.
Fu X; Lei T; Chen C; Fu G
Colloids Surf B Biointerfaces; 2024 Feb; 234():113725. PubMed ID: 38157764
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
[TBL] [Abstract][Full Text] [Related]
38. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels.
Lindgren SH; Andersson TL; Vinge E; Andersson KE
Acta Physiol Scand; 1990 Oct; 140(2):209-19. PubMed ID: 2176433
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of platelet signal transduction as anti-aggregatory drugs.
Geiger J
Expert Opin Investig Drugs; 2001 May; 10(5):865-90. PubMed ID: 11322863
[TBL] [Abstract][Full Text] [Related]
40. Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes.
Matsunaga H; Hokari R; Higashiyama M; Kurihara C; Okada Y; Watanabe C; Komoto S; Nakamura M; Kawaguchi A; Nagao S; Miura S
Am J Physiol Gastrointest Liver Physiol; 2009 Dec; 297(6):G1077-84. PubMed ID: 19815627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
